Endometrial hyperplasia. Endometrial hyperplasia
Conditions
Interventions
Intervention 1: Control group:Patients in the control group, will be treated with megestrol acetate at a daily dose of 80mg(Aboureihan Pharmaceuticals Iran]). Patients will be observed fo
Sponsors
Vice chancellor for Research,Tabriz University Of Medical Sciences
Eligibility
Sex/Gender
Female
Age
38 Years to 55 Years
Inclusion criteria
Inclusion criteria: Age of 38 to 55 years Women with abnormal uterine bleeding and proliferative endometrium with irregular glands Willingness to participate in the study BMI between 18.5 and 29.99
Exclusion criteria
Exclusion criteria: Atypical hyperplasia and endometrial cancer diagnosis History of hormone therapy in the last 3 months Not consent to participate in the study Diabetes History of depression and use of antidepressants Coagulation disorders Hypertension Seizures and the use of antiepileptic drugs Having autoimmune diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histologic types of endometrium. Timepoint: Three months after the first dose of the drug. Method of measurement: Microscopic examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Parvin Mostafa Gharabaghi
Tabriz University of Medical Sciences
Outcome results
None listed